fabian
sesterhenn
jaum
bonet
bruno
e
correia
vaccin
one
success
intervent
global
health
howev
tradit
vaccin
develop
proven
insuffici
deal
pathogen
elud
immun
system
highli
variabl
nonfunct
epitop
emerg
b
cell
technolog
yield
potent
monoclon
antibodi
target
conserv
epitop
structur
character
provid
templat
ration
immunogen
design
review
immunogen
design
strategi
leverag
structur
inform
steer
bulk
immun
respons
toward
induct
precis
antibodi
specif
target
key
antigen
site
immunogen
design
elicit
welldefin
antibodi
respons
becom
basi
dub
precis
vaccin
immunogen
use
tackl
longstand
vaccin
problem
demonstr
potenti
seed
nextgener
vaccin
vaccin
like
efficaci
prophylact
approach
modern
medicin
greatli
reduc
burden
infecti
diseas
despit
numer
success
classic
vaccin
strategi
reli
attenu
inactiv
pathogen
formul
fail
elicit
neutral
antibodi
number
pathogen
notabl
exampl
longstand
viral
threat
like
human
immunodefici
viru
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
dengu
well
emerg
pathogen
zika
amongst
other
addit
constant
antigen
drift
influenza
requir
formul
season
vaccin
prevent
develop
univers
protect
vaccin
mani
pathogen
evolv
strategi
evad
target
neutral
immun
respons
immunodomin
antigen
site
confer
broad
potent
neutral
target
potent
neutral
antibodi
nab
poorli
understood
phenomenon
well
establish
nonneutr
antibodi
facilit
viru
entri
host
cell
differ
serotyp
certain
pathogen
eg
dengu
therebi
caus
antibodi
depend
diseas
enhanc
ade
overcom
current
limit
vaccin
develop
ration
vaccin
strategi
known
revers
vaccinolog
propos
aim
focu
immun
respons
epitop
pathogen
vulner
antibodymedi
neutral
essenc
strategi
reli
isol
nab
human
anim
repertoir
follow
structur
character
nabantigen
complex
final
exploit
acquir
atomiclevel
inform
design
novel
immunogen
key
challeng
nextgener
vaccin
place
neutral
epitop
immun
system
spotlight
effici
recognit
enhanc
epitopespecif
antibodi
elicit
refer
class
vaccin
precis
vaccin
given
extrem
welldefin
epitopedirect
antibodi
respons
essenti
requisit
precis
vaccin
encod
structur
inform
epitop
target
broad
potent
neutral
antibodi
design
immunogen
review
four
structurebas
immunogen
design
approach
aim
elicit
focus
antibodi
respons
silenc
nonneutr
epitop
ii
conform
stabil
iii
germlin
target
iv
epitop
scaffold
special
emphasi
place
link
design
strategi
immunolog
outcom
differ
pathogen
figur
intuit
strategi
focu
antibodi
respons
immunolog
subdomin
epitop
remov
mask
nonneutr
epitop
section
describ
two
approach
favor
immun
recognit
conserv
epitop
excis
antigen
domain
mainli
target
nonneutr
antibodi
ii
reduc
access
nonneutr
epitop
glycan
mask
influenza
viru
hemagglutinin
ha
surfac
protein
main
target
humor
respons
one
notori
exampl
antibodi
respons
mostli
target
highli
sequenc
variabl
region
head
domain
yield
mostli
strain
specif
respons
despit
immunodomin
toward
head
domain
sever
epitop
ha
stem
region
target
broadli
neutral
antibodi
bnab
provid
strong
rational
vaccin
aim
induc
antibodi
respons
toward
ha
stem
two
independ
studi
report
design
immunogen
compris
hastem
domain
sever
round
structurebas
design
perform
includ
remov
entir
head
domain
follow
introduct
stabil
core
mutat
linker
design
upon
vaccin
stem
deriv
antigen
mice
ferret
cynomolgu
monkey
mount
crossreact
antibodi
respons
surviv
challeng
lethal
dose
highli
pathogen
viral
isol
contrast
ha
major
target
respiratori
syncyti
viru
rsv
neutral
antibodi
head
domain
fusion
protein
rsvf
boyington
engin
design
glossari
immunogen
complet
antigen
compos
macromolecular
carrier
one
multipl
epitop
capabl
induc
immun
respons
immunodomin
immun
respons
preferenti
target
certain
antigen
antigen
site
precis
vaccin
vaccin
compos
design
immunogen
elicit
antibodi
respons
direct
key
antigen
site
sensit
neutral
broadli
neutral
antibodi
bnab
neutral
antibodi
broadli
effect
differ
strain
pathogen
germlin
antibodi
unmut
antibodi
repertoir
encod
variabl
v
divers
join
j
gene
structurebas
approach
immunogen
design
four
main
strategi
use
design
improv
immunogen
elicit
neutral
antibodi
target
precis
conform
state
epitop
antibodi
lineag
center
strategi
employ
stabil
viral
fusion
protein
enhanc
antibodi
respons
toward
neutral
epitop
locat
viral
fusion
protein
centerbottom
structurebas
approach
classifi
accord
expect
epitop
specif
neutral
potenc
elicit
antibodi
respons
mask
nonneutr
epitop
glycosyl
also
led
novel
envelop
env
immunogen
reduc
antigen
nonneutr
epitop
two
main
target
nonnab
flexibl
env
loop
well
bottom
recombin
env
inaccess
membranebound
env
spike
introduct
two
glycan
shown
dampen
immun
respons
site
upon
rabbit
immun
similarli
glycosyl
env
base
show
reduc
reactiv
sera
anim
immun
nonmask
env
indic
glycan
mask
render
nonneutr
epitop
inaccess
overal
domain
delet
mask
epitop
induc
measur
immunolog
outcom
nevertheless
seem
radic
transform
immun
respons
obtain
perhap
promis
ha
headless
immunogen
elicit
antibodi
increas
reactiv
across
heterosubtyp
influenza
strain
virus
depend
enter
host
cell
replic
process
mediat
viral
surfac
protein
higher
postfus
f
calv
confer
full
protect
upper
lower
respiratori
tract
upon
viral
challeng
structur
similar
rsv
hmpv
allow
similar
design
strategi
stabil
mpvf
prefus
state
interestingli
immun
studi
mice
yield
higher
neutral
antibodi
respons
elicit
postfus
conform
show
although
design
strategi
seem
transfer
pathogen
fusion
protein
immunolog
outcom
differ
largest
class
fusion
protein
found
human
coronavirus
known
spike
protein
structur
spike
protein
human
coronaviru
solv
serv
templat
stabil
merscov
spike
protein
prefus
conform
immunogen
studi
mice
reveal
prefus
merscov
elicit
neutral
antibodi
increas
breadth
potenc
compar
postfus
show
particular
protein
antigen
conform
stabil
strategi
yield
superior
immunolog
outcom
use
analog
design
strategi
extens
effort
made
stabil
hiv
env
glycoprotein
prefus
close
conform
particular
challeng
env
engin
maintain
nativ
conform
upon
recombin
express
reduc
conform
breath
open
close
conform
report
prefus
env
wide
use
construct
nativelik
env
design
trimer
stabil
intermolecular
disulfid
bond
isoleucineprolin
substitut
within
fusion
peptid
truncat
remov
hydrophob
membran
proxim
region
comprehens
analysi
effort
stabil
env
beyond
scope
articl
subject
sever
review
highlight
two
recent
studi
employ
ration
stabil
strategi
suppress
nonneutr
antibodi
respons
env
loop
major
target
nonneutr
ab
expos
env
open
conform
engin
env
show
reduc
bind
antibodi
target
epitop
neither
studi
could
prove
direct
impact
modif
antibodi
specif
neutral
vivo
summari
antigen
conform
stabil
clearli
one
promis
strategi
immunogen
engin
shown
abil
dramat
transform
immunolog
outcom
present
relev
antigen
conform
elicit
function
antibodi
strategi
precis
charact
aris
conform
specif
rather
epitop
specif
much
domin
follow
design
strategi
typic
bnab
carri
larg
number
somat
hypermut
base
observ
germlin
target
emerg
novel
strategi
elicit
well
defin
antibodi
lineag
germlin
target
aim
engag
unmut
precursor
bnab
drive
matur
toward
bnab
gradual
acquir
necessari
somat
mutat
broadli
neutral
use
comput
design
vitro
evolut
jardin
et
al
develop
engin
outer
domain
eod
viral
protein
introduc
mutat
enabl
bind
infer
germlin
precursor
bnab
heavi
chain
knockin
mous
model
mice
transgen
human
immunoglobulin
loci
shown
germlin
target
immunogen
prime
antibodi
characterist
featur
antibodi
prime
b
cell
shown
recal
upon
boost
immun
gradual
nativ
env
version
somat
mutat
driven
toward
found
bnab
similarli
medinaramirez
et
al
engin
trimer
bind
germlin
precursor
antibodi
engin
nativelik
trimer
shown
activ
antibodi
vitro
vivo
order
target
anoth
bnab
class
bind
differ
epitop
env
bnab
steichen
et
al
employ
mammalian
cell
surfac
display
engin
germlin
target
env
trimer
shown
activ
b
cell
carri
germlin
receptor
vitro
prime
antibodi
respons
knockin
mice
togeth
studi
establish
first
mileston
use
structurebas
design
togeth
stepwis
vaccin
protocol
target
expand
specif
germlin
precursor
albeit
import
contribut
remain
shown
outcom
germlin
target
strategi
term
elicit
broadli
neutral
antibodi
relev
anim
model
unlik
describ
approach
precis
aspect
strategi
relat
specif
antibodi
lineag
deem
necessari
achiev
broad
hiv
neutral
activ
present
singl
epitop
context
scaffoldprotein
gain
traction
last
year
aim
elicit
epitopespecif
antibodi
essenti
approach
use
structur
inform
exact
epitop
conform
recogn
nab
design
heterolog
protein
mimic
structur
epitop
structur
compat
antibodi
bind
mode
first
report
epitopescaffold
present
context
hiv
use
target
neutral
epitop
two
studi
epitop
graft
onto
heterolog
scaffoldprotein
use
comput
design
approach
biochem
structur
character
confirm
accur
epitop
mimicri
immunolog
remark
result
epitopescaffold
abl
induc
antibodi
fine
specif
similar
parent
antibodi
show
epitopescaffold
achiev
vivo
immunolog
outcom
primarili
design
although
serum
neutral
obtain
later
effort
mclellan
colleagu
appli
epitop
scaffold
strategi
design
immunogen
present
antigen
site
ii
rsvf
target
fdaapprov
monoclon
antibodi
palivizumab
howev
side
chain
epitop
graft
onto
scaffold
similar
backbon
conform
epitop
yield
scaffold
imperfect
epitop
mimicri
much
like
hiv
epitopescaffold
mous
immun
epitopespecif
antibodi
elicit
serum
neutral
achiev
improv
structur
mimicri
site
ii
synthet
scaffold
correia
et
al
develop
new
protein
design
algorithm
protein
fold
sequenc
design
simul
coupl
gener
immunogen
epitop
structur
stabil
exact
nativ
conform
design
show
extrem
high
affin
site
ii
antibodi
structur
character
reveal
perfect
epitop
mimicri
mous
immunogen
studi
secondgener
epitopescaffold
still
elicit
viral
neutral
titer
nevertheless
use
nonhuman
primat
nhp
low
consist
level
neutral
detect
monoclon
antibodi
isol
nhp
site
iispecif
bound
high
affin
rsvf
structur
studi
confirm
elicit
antibodi
recogn
antigen
site
ii
similarli
palivizumab
importantli
neutral
rsv
superior
potenc
compar
palivizumab
summari
epitopescaffold
approach
effici
way
elicit
epitopespecif
antibodi
nevertheless
simplifi
immunogen
mostli
encod
epitop
bind
motif
surfac
lack
import
molecular
featur
regard
tertiari
quaternari
environ
nativ
viral
protein
class
immunogen
face
import
challeng
despit
proven
abil
induc
potent
epitop
specif
antibodi
remain
seen
increas
fraction
function
antibodi
within
overal
repertoir
field
vaccinolog
face
incred
challeng
develop
efficaci
vaccin
sophist
pathogen
abil
escap
immun
respons
mani
differ
way
due
escap
mechan
mount
antibodi
respons
pathogen
limit
breadth
afford
protect
antigen
drift
strain
addit
induc
neutral
titer
often
low
decay
time
allow
reinfect
revers
vaccinolog
strategi
envis
integr
approach
design
immunogen
elicit
boost
preexist
antibodi
respons
focus
bona
fide
neutral
epitop
age
system
approach
bigdata
scienc
understand
complex
biolog
phenomena
immun
respons
huge
expand
therefor
abl
defin
exquisit
accuraci
molecular
determin
desir
particular
vaccin
develop
endeavor
determin
includ
limit
antigen
conform
desir
antibodi
lineag
key
neutral
epitop
lead
us
conclud
enter
new
age
precis
vaccin
structurebas
approach
review
essenti
defin
target
problem
realiz
full
potenti
precis
vaccin
despit
success
far
none
strategi
describ
proven
onefitsal
solut
prefus
stabil
rsvf
far
superior
immunogen
postfus
counterpart
approach
mpvf
enhanc
neutral
respons
similarli
sole
conform
stabil
hiv
env
deem
unlik
elicit
bnab
germlin
target
approach
hold
great
promis
prime
bnab
respons
final
epitopescaffold
elicit
potent
specif
monoclon
antibodi
nhp
averag
neutral
titer
rather
low
strength
weak
present
strategi
suggest
complex
balanc
approach
target
pathogen
expect
immun
respons
ultim
combin
differ
strategi
may
best
cours
action
overcom
specif
limit
bring
forth
new
gener
ration
design
precis
vaccin
reduc
exposur
nonneutr
epitop
nativelik
env
trimer
kulpet
al
employ
comput
structureguid
design
reduc
exposur
epitop
three
env
antigen
site
addit
glycosyl
site
introduc
block
antibodi
access
membran
proxim
region
network
buri
hydrophil
residu
replac
hydrophob
residu
lock
conform
addit
multist
design
protocol
use
abrog
receptor
bind
retain
affin
bnab
ration
design
approach
dampen
immunogen
nonneutr
epitop
could
potenti
employ
pathogen
germlin
target
activ
germlin
precursor
human
mice
sequenti
boost
protocol
select
product
somat
mutat
hiv
epitop
scaffold
elicit
epitop
specif
antibodi
success
elicit
rsv
antibodi
superior
neutral
potenc
compar
clinic
approv
mab
hiv
rsv
